住院COVID-19患者深静脉血栓研究
该回顾性研究比较了COVID-19与非COVID-19住院患者深静脉血栓(DVT)的发生情况,发现COVID-19患者DVT发生率更高(31% vs 19%),且更多为远端和双侧。多变量分析显示男性、ICU入住和ECMO与DVT独立相关。作者支持对低出血风险的重症COVID-19患者经验性启动治疗性抗凝。
要点
- COVID-19住院患者DVT发生率显著高于非COVID-19患者(31% vs 19%)。
- COVID-19患者DVT更多位于远端(63% vs 29%)和双侧(15% vs 4%)。
- 男性、ICU入住和ECMO是COVID-19患者DVT的独立危险因素。
核心结论
- COVID-19住院患者DVT发生率高于非COVID-19住院患者,且远端和双侧DVT更常见。
- 支持对低出血风险的重症COVID-19患者经验性启动治疗性抗凝,超声检查应保留给高度怀疑静脉血栓栓塞且抗凝可能导致危及生命后果的患者。
研究设计与样本
- 回顾性分析2020年3月3日至4月12日在纽约市学术健康系统接受上肢或下肢静脉双功超声检查的所有COVID-19患者,随访至2020年5月12日。
- 对照队列为2019年12月1日至12月31日接受静脉双功超声检查的非COVID-19住院患者。
- 共纳入443例患者(COVID-19组188例,非COVID-19组255例),主要结局为DVT。
主要发现
- COVID-19组DVT发生率为31%,非COVID-19组为19%(P = .005)。
- 肺栓塞发生率两组无统计学显著差异(8% vs 4%;P = .105)。
- COVID-19组DVT更常位于远端(63% vs 29%;P < .001)和双侧(15% vs 4%;P < .001)。
- COVID-19组DVT患者中42例(72%)抗血栓治疗升级,非DVT组中49例(38%)升级、3例(2%)降级(P < .001)。
- COVID-19队列中,DVT组入院时D-二聚体水平显著更高(2746 ng/mL vs 1481 ng/mL;P = .004),超声检查时也更高(6068 ng/mL vs 3049 ng/mL;P < .01)。
关键数值与推荐
- 多变量分析显示男性(OR 2.27;95%CI 1.06-4.87;P = .035)、ICU入住(OR 3.42;95%CI 1.02-11.44;P = .046)和ECMO(OR 5.5;95%CI 1.01-30.13;P = .049)与DVT独立相关。
临床怎么用
- 对于低出血风险的重症COVID-19患者,可考虑经验性启动治疗性抗凝。
- 静脉双功超声应保留用于高度怀疑静脉血栓栓塞且抗凝治疗可能导致危及生命后果的患者。
局限性
- 本研究为单中心回顾性分析,样本量有限,可能存在选择偏倚。
- 对照组来自不同时间段,可能存在时间相关的混杂因素。
- 需要进一步研究阐明COVID-19患者血管血栓栓塞事件的病因并指导预防和治疗干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The pandemic of coronavirus disease 2019 (COVID-19) has caused devastating morbidity and mortality worldwide. In particular, thromboembolic complications have emerged as a key threat for patients with COVID-19. We assessed our experience with deep vein thrombosis (DVT) in patients with COVID-19. METHODS: We performed a retrospective analysis of all patients with COVID-19 who had undergone upper or lower extremity venous duplex ultrasonography at an academic health system in New York City from March 3, 2020 to April 12, 2020 with follow-up through May 12, 2020. A cohort of hospitalized patients without COVID-19 (non-COVID-19) who had undergone venous duplex ultrasonography from December 1, 2019 to December 31, 2019 was used for comparison. The primary outcome was DVT. The secondary outcomes included pulmonary embolism, in-hospital mortality, admission to the intensive care unit, and antithrombotic therapy. Multivariable logistic regression was performed to identify the risk factors for DVT and mortality. RESULTS: Of 443 patients (COVID-19, n = 188; and non-COVID-19, n = 255) who had undergone venous duplex ultrasonography, the COVID-19 cohort had had a greater incidence of DVT (31% vs 19%; P = .005) than had the non-COVID-19 cohort. The incidence of pulmonary embolism was not significantly different statistically between the COVID-19 and non-COVID-19 cohorts (8% vs 4%; P = .105). The DVT location in the COVID-19 group was more often distal (63% vs 29%; P < .001) and bilateral (15% vs 4%; P < .001). The duplex ultrasound findings had a significant impact on the antithrombotic plan; 42 patients (72%) with COVID-19 in the DVT group had their therapy escalated and 49 (38%) and 3 (2%) had their therapy escalated and deescalated in the non-DVT group, respectively (P < .001). Within the COVID-19 cohort, the D-dimer level was significantly greater in the DVT group at admission (2746 ng/mL vs 1481 ng/mL; P = .004) and at the duplex examination (6068 ng/mL vs 3049 ng/mL; P < .01). On multivariable analysis, male sex (odds ratio [OR], 2.27; 95% confidence interval [CI], 1.06-4.87; P = .035), intensive care unit admission (OR, 3.42; 95% CI, 1.02-11.44; P = .046), and extracorporeal membrane oxygenation (OR, 5.5; 95% CI, 1.01-30.13; P = .049) were independently associated with DVT. CONCLUSIONS: Given the high incidence of venous thromboembolic events in this population, we support the decision to empirically initiate therapeutic anticoagulation for patients with a low bleeding risk and severe COVID-19 infection. Duplex ultrasonography should be reserved for patients with a high clinical suspicion of venous thromboembolism for whom anticoagulation therapy could result in life-threatening consequences. Further study of patients with COVID-19 is warranted to elucidate the etiology of vascular thromboembolic events and guide the prophylactic and therapeutic interventions for these patients.
引用
- Chang H, Rockman CB, Jacobowitz GR, et al. Deep vein thrombosis in hospitalized patients with coronavirus disease 2019. J Vasc Surg Venous Lymphat Disord. 2020. PMID: 33039545. doi:10.1016/j.jvsv.2020.09.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。